Anglia Ruskin University: Targeting Annexin-A1 Can Halt Cancer Cell Growth
January 20, 2024
January 20, 2024
CAMBRIDGE, England, Jan. 20 (TNSres) -- Anglia Ruskin University issued the following news:
A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.
The research was led by Professor Chris Parris and Dr Hussein Al-Ali at Anglia Ruskin University (ARU) in collaboration with Professor Chri . . .
A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.
The research was led by Professor Chris Parris and Dr Hussein Al-Ali at Anglia Ruskin University (ARU) in collaboration with Professor Chri . . .